Company / SG&A per Share
BioMarin Pharmaceutical SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$6.00
FY2025
5-year range
$4.18 / $6.00
FY2021-FY2025
Trend
+13.4%
vs FY2024
Sector context
#28 of 210
Health Care
What the data says
BioMarin Pharmaceutical's sg&a per share of $6.00 is higher than 87% of companies in the Health Care sector (FY2025). SG&A per Share has increased for 9 consecutive years, from $2.76 in FY2016 to $6.00 in FY2025.
Based on SEC 10-K filings.
6.00 in FY2025 with a 5-year CAGR of +8.1%. Top quartile in the Health Care sector.
Increased from $4.73 to $6.00 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +10.7%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 210This company $6.00 Sector average $40.75
▼
-85.3% below sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's sg&a per share has grown for 9 consecutive years.
- In FY2025, sg&a per share increased 13.4% year-over-year.
- Ranks #28 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.00 | +13.4% |
| FY2024 | $5.29 | +11.8% |
| FY2023 | $4.73 | +7.1% |
| FY2022 | $4.42 | +5.8% |
| FY2021 | $4.18 | +2.9% |
| FY2020 | $4.06 | +7.2% |
| FY2019 | $3.79 | +11.7% |
| FY2018 | $3.39 | +7.5% |
| FY2017 | $3.15 | +14.2% |
| FY2016 | $2.76 | +10.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026